5 results
hematology diagnosis syndrome algorithm anticoagulation apml cancer chemotherapy cyp3a4 differentiation diuresis diuretics excretion inducers inhibitors interactions malignancy medications nephrology pglycoprotein
Patient risk stratification algorithm for the treatment of cancer-associated thrombosis. Currently, edoxaban and rivaroxaban are the only
algorithm for the treatment ... anticoagulants (DOACs ... thrombosis; PE = pulmonary ... Anticoagulation #Management ... #Hematology #Oncology
►
 (DOAC interactions) Cancer-treatment specific inducers (↑) and inhibitors (↓) of cytochrome p450 CYP3A4 and P-glycoprotein. DOACs are substrates
(DOAC interactions ... ) Cancer-treatment ... #Chemotherapy #Oncology ... #Hematology #Interactions ... #Table #Pharmacology
Differentiation Syndrome in APML Epidemiology: • Incidence: common in APL (2-48% depending on the study) • Triggers:
Triggers: ATRA treatment ... Imaging: CXR- pulmonary ... Renal Failure Treatment ... APML #diagnosis #management ... #hematology #oncology
Diuretics and Agents Regulating Renal Excretion Carbonic Anhydrase Inhibitors (Acetazolamide, Dichlorphenamide) • Glaucoma • Epilepsy • Altitude
irrigation • Management ... Torsemide) • Acute pulmonary ... Tolvaptan) • Treatment ... Diuresis #Nephrology #Pharmacology ... #Medications #Table
Sjogren's Syndrome Overview Epidemiology: • F > M: 9:1 • 5-6th Decades (can be any age) Autoimmune exocrinopathy multisystemic disease
, INC risk PE, Pulmonary ... Adenocarcinoma Treatment ... lubricants • Pharmacologic ... Sjogrens #Syndrome #Rheumatology ... #Diagnosis #Management
No results found for "Lever treatment management pulmonary rheumatology pharmacology oncology doac toxicity table"
Try removing search terms or sorting by relevance
Or Upload an image for you and others searching for #Lever #treatment #management #pulmonary #rheumatology #pharmacology #oncology #doac #toxicity #table